Anónimo. FDA approval of cenegermin marks three firsts in drug history . DIA Daily 2018:24 de agosto. [Ref.ID 102813]

Anónimo. Muscle drug determined too expensive for UK’s NHS. DIA Daily 2018:14 de agosto. [Ref.ID 102787]

Desjardins A, Gromeier M, Herndon II JE, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 2018;379:12 de juliol. [Ref.ID 102734]

Anónimo. EMA’s CHMP recommends approval for plaque psoriasis drug. DIA Daily 2018:4. [Ref.ID 102730]

Feuerstein A. Juno Therapeutics could shake up CAR-T market with strong lymphoma data. STAT 2017:1. [Ref.ID 102111]

Anónimo. FDA Approves CAR-T therapy for treatment of childhood leukemia. DIA Daily 2017:1. [Ref.ID 102036]

Anónimo. Gilead agrees to acquire Kite Pharma in $11.9 billion deal. DIA Daily 2017:1. [Ref.ID 102034]

Anónimo. NICE considers eliminating Sanofi, Ipsen thyroid cancer drugs From Cancer Drug Fund. DIA Daily 2017:2. [Ref.ID 102033]

Eunjung Cha A. Monthly shot could be the ‘next revolution’ in HIV therapy, replacing daily pills. The Washington Post 2017:1. [Ref.ID 101921]

Feuerstein A. STAT Plus: Strong results for a new HIV drug will be a big boost to Gilead Sciences. STAT 2017:24 de julio. [Ref.ID 101919]

Anónimo. FDA approves guselkumab for treatment of plaque psoriasis. DIA Daily 2017:2. [Ref.ID 101909]

Anónimo. Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC. Med Lett Drugs Ther 2017;59:22-3. [Ref.ID 101421]

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, de Marinis F, Turna H, Lee J-S, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR, OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255-65. [Ref.ID 101392]

Anónimo. Blinatumomab for acute lymphoblastic leukaemia. Australian Prescriber 2016;39:221. [Ref.ID 101023]

Anónimo. Crizotinib en première ligne dans certains cancers bronchiques. Prescrire 2016;36:891-2. [Ref.ID 101005]

Anónimo. Pembrolizumb et mélanomes métastasés ou inopérables. Prescrire 2016;36:889-91. [Ref.ID 101003]

Anónimo. Carfilzomib et myélome multiple. Prescrire 2016;36:885-6. [Ref.ID 101002]

Anónimo. FDA approves rucaparib to treat patients with ovarian cancer whose tumors have BRCA mutation. DIA Daily 2016:1. [Ref.ID 101001]

Anónimo. Juno suspends clinical trial after two additional patient deaths. DIA Daily 2016:4. [Ref.ID 100980]

Anónimo. UK’s NICE recommends ibrutinib after discount. DIA Daily 2016:2. [Ref.ID 100979]